Combining trifluridine/tipiracil with fufuquitinib for treating advanced colorectal cancer

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib Versus Trifluridine/Tipiracil and Fufuquitinib for Third-line Treatment of Unresectable Metastatic Colorectal Cancer

This study is testing if a new combination of two cancer drugs can help people with advanced colorectal cancer who haven't responded to other treatments.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: First Affiliated Hospital of Wenzhou Medical University (other)
• Drugs / interventions: fufuquitinib
• Locations: 1 site (Wenzhou, Zhejiang)
• Trial ID: NCT06485713 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the efficacy and safety of a combination therapy using trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer who have previously failed standard treatments. The study aims to determine whether this combination is more effective than using each drug alone. Participants will be monitored for treatment response and safety outcomes throughout the trial. The study is designed for patients aged 18-75 with specific health criteria and measurable disease.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with advanced colorectal adenocarcinoma who have failed first- and second-line treatments.

Not a fit: Patients with colorectal cancer who have not yet received standard treatments or those with other significant health issues may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients with advanced colorectal cancer who have limited treatment choices.

How similar studies have performed: While this approach is novel, similar combination therapies have shown promise in other studies, indicating potential for success.

Eligibility criteria

Inclusion Criteria:

* 1.Age 18-75 (at the time of signing the informed consent);ECOG PS score: 0-1; Expected survival time \> 3 months.

  2.Patients with advanced colorectal adenocarcinoma confirmed by histopathology who had failed standard first - and second-line treatment.

  3.At least 1 measurable lesion was present according to RECIST1.1 criteria. 4.Good organ function, laboratory tests meet the following criteria:
  1. Hemoglobin ≥90g/L;Absolute count of neutrophils (ANC) ≥1.5×109/L;Platelet ≥100×109/L;
  2. ALT and AST≤2.5 upper limit of normal (ULN).ALP≤2.5 ULN;(if liver metastases ≤5 ULN);
  3. Total bilirubin (TBIL) \< 1.5 ULN;
  4. Serum creatinine (CR) \<1.5 ULN or creatinine clearance (CCR) ≥50ml/min;
  5. Serum albumin ≥30g/L;
  6. International Normalized ratio (INR), prothrombin time (PT), activated partial thrombin time (APTT) ≤1.5ULN;
  7. Thyrotropin (TSH) ≤ULN;If abnormal, T3 and T4 levels should be investigated, and normal levels can be included.

     5.cardiac color ultrasound: Left ventricular ejection fraction (LVEF) ≥50%. 6.Hypertension was well controlled. 7.Female participants of reproductive age should agree to use contraception during the study period and for 6 months after the study ends; Serum pregnancy test was negative within 7 days prior to study enrollment,and should be Non-lactation stage. Male subjects should agree to use contraception during the study period and for 6 months after the study ends.

     Exclusion Criteria:
* 1.Combined disease or history

  1. .Present or present with other malignancies within 3 years.
  2. .Have multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea, or intestinal obstruction)
  3. .Gastrointestinal bleeding or perforation occurred during the first 4 weeks of enrollment
  4. .Patients with ulcerative colitis, Crohn's disease, and active inflammatory bowel disease during the first 4 weeks of enrollment
  5. .Uncontrolled pleural effusion, ascites, and moderate or greater pericardial effusion
  6. .Unmitigated toxic reactions above grade 1 of CTC AE due to any previous treatment, excluding alopecia.
  7. .Received major surgical treatment or significant traumatic injury within 28 days prior to enrollment
  8. .Patients with hematemesis, hematochezia, or any bleeding event ≥ CTCS AE level 3 within the previous 3 months, or with any signs of bleeding or history determined by the investigator to be ineligible for enrollment
  9. .Arteriovenous thrombosis occurred within 6 months, such as cerebrovascular accident, pulmonary embolism, etc
  10. .A history of psychotropic substance abuse and inability to abstain
  11. .Subjects with any severe and/or uncontrolled disease, including

      1. Uncontrolled hypertension
      2. Unstable angina pectoris / ≥ grade 2 cardiogenic chest pain;Myocardial infarction occurred within 12 months before randomization;≥ grade 2 heart failure;Restrictive heart disease;≥ grade 2 atrioventricular block, arrhythmia that cannot be stably controlled with drugs.
      3. Active infection
      4. Decompensated cirrhosis, active hepatitis;
      5. Renal failure requires hemodialysis or peritoneal dialysis
      6. A history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation

      h.Diabetes with poorly controlled i.Urine routine showed urine protein ≥++, and 24h albuminuria quantitative \> 1.0 g g.History of neurological or psychiatric disorders 2.Subjects who, in the investigator's judgment, have a concomitant medical condition that seriously endangers subjects' safety or interferes with the completion of the study, or are deemed unsuitable for enrollment for other reasons.

Where this trial is running

Wenzhou, Zhejiang

• The First Affiliated Hospital of Wenzhou Medical University — Wenzhou, Zhejiang, China (RECRUITING)

Conditions: Metastatic Colorectal Cancer, Drug Therapy, Fufuquitinib, trifluridine/tipiracil, Combination therapy